Archive for Stock Market News

Dow logs second record in a row

By IFCMarkets

Dollar rebounds on surprise Manufacturing PMI beat

US stock market ended marginally lower on Friday despite second consecutive record close of Dow Jones industrial average. S&P 500 slipped 0.04% to 2929.48, closing 0.9% higher for the week. Dow Jones industrial average rose 0.3% to record high 26732. The Nasdaq lost 0.5% to 7986.96. The dollar strengthening resumed as Markit’s manufacturing PMI rose to 55.6 in September from the previous reading of 54.7 when a reading of 55.1 was forecast: the live dollar index data show the ICE US Dollar index, a measure of the dollar’s strength against a basket of six rival currencies, gained 0.3% to 94.178 and is higher currently. Futures on stock indices point to lower openings today.

DJI logs second consecutive record above January levels 09/24/2018 Market Overview IFCM Markets chart

FTSE 100 opens lower than other European markets

European stocks ended high on Friday led by financial and energy shares. Both the GBP/USD and EUR/USD turned lower after European Union leaders rejected Prime Minister Theresa May’s post-Brexit proposal on Thursday but both pairs are higher currently. The Stoxx Europe 600 Index added 0.4%, booking 1.7% gain for the week. The DAX 30 rose 0.9% to 12430.88. France’s CAC 40 added 0.8% and UK’s FTSE 100 jumped 1.7% to 7490.23. Indices opened 0.2% – 0.3% lower today

Asian indices retreat

Asian stock indices are mostly lower today with several markets, including those in Japan and China, closed for a holiday. Stock market in Hong Kong is falling with the Hang Seng Index 1.7% lower. Australia’s All Ordinaries Index slipped 0.1% despite the Australian dollar turn lower against the greenback.

Brent futures prices are solidly higher today after OPEC’s leader Saudi Arabia and Russia indicated no immediate, additional increase in crude output on Sunday despite President Donald Trump’s calls for action to expand the output ahad of Iran sanctions. Prices rose Friday: Brent for November settlement added 0.1% to close at $78.80 a barrel Friday, rising 0.9% for the week.

Market Analysis provided by IFCMarkets

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

S&P500 Mini Speculators advanced their bullish net positions

Sept. 22, 2018 – By CountingPips.comReceive our weekly COT Reports by Email

S&P500 Mini Non-Commercial Speculator Positions:

Large stock market speculators boosted their bullish net positions in the S&P500 Mini futures markets this week, according to the latest Commitment of Traders (COT) data released by the Commodity Futures Trading Commission (CFTC) on Friday.

The non-commercial futures contracts of S&P500 Mini futures, traded by large speculators and hedge funds, totaled a net position of 149,962 contracts in the data reported through Tuesday September 18th. This was a weekly gain of 27,742 contracts from the previous week which had a total of 122,220 net contracts.

This week’s rebound in bullish bets followed last week’s sharp decline (-40,012 contracts) that brought the spec position to the lowest level in twenty-six weeks. The gain this week pushed the current standing back over the +140,000 net contract level for the third time out of the past four weeks.

S&P500 Mini Commercial Positions:

The commercial traders position, hedgers or traders engaged in buying and selling for business purposes, totaled a net position of -239,851 contracts on the week. This was a weekly uptick of 12,626 contracts from the total net of -252,477 contracts reported the previous week.

S&P500 Mini Futures:

Over the same weekly reporting time-frame, from Tuesday to Tuesday, the S&P500 Mini Futures (Front Month) closed at approximately $2911.75 which was an advance of $22.0 from the previous close of $2889.75, according to unofficial market data.

*COT Report: The COT data, released weekly to the public each Friday, is updated through the most recent Tuesday (data is 3 days old) and shows a quick view of how large speculators or non-commercials (for-profit traders) as well as the commercial traders (hedgers & traders for business purposes) were positioned in the futures markets. The CFTC categorizes trader positions according to commercial hedgers (traders who use futures contracts for hedging as part of the business), non-commercials (large traders who speculate to realize trading profits) and nonreportable traders (usually small traders/speculators). Find CFTC criteria here: (http://www.cftc.gov/MarketReports/CommitmentsofTraders/ExplanatoryNotes/index.htm).

Article By CountingPips.comReceive our weekly COT Reports by Email

VIX Speculators edged their bearish net positions lower for 2nd week

Sept. 22, 2018 – By CountingPips.comReceive our weekly COT Reports by Email

VIX Non-Commercial Speculator Positions:

Large volatility speculators trimmed their bearish net positions slightly lower in the VIX futures markets this week, according to the latest Commitment of Traders (COT) data released by the Commodity Futures Trading Commission (CFTC) on Friday.

The non-commercial futures contracts of VIX futures, traded by large speculators and hedge funds, totaled a net position of -119,774 contracts in the data reported through Tuesday September 18th. This was a weekly advance of 658 contracts from the previous week which had a total of -120,432 net contracts.

The bearish speculative position has now fallen for two straight weeks after bearish bets had risen for eight out of the previous nine weeks. The current standing has dipped below the -120,000 contract level for the first time in three weeks but remains highly bearish and over the -100,000 contract threshold for an eighth week in a row.

VIX Commercial Positions:

The commercial traders position, hedgers or traders engaged in buying and selling for business purposes, totaled a net position of 125,136 contracts on the week. This was a weekly drop of -1,161 contracts from the total net of 126,297 contracts reported the previous week.

VIX Futures:

Over the same weekly reporting time-frame, from Tuesday to Tuesday, the VIX Futures (Front Month) closed at approximately $14.67 which was a shortfall of $-0.45 from the previous close of $15.12, according to unofficial market data.

*COT Report: The COT data, released weekly to the public each Friday, is updated through the most recent Tuesday (data is 3 days old) and shows a quick view of how large speculators or non-commercials (for-profit traders) as well as the commercial traders (hedgers & traders for business purposes) were positioned in the futures markets. The CFTC categorizes trader positions according to commercial hedgers (traders who use futures contracts for hedging as part of the business), non-commercials (large traders who speculate to realize trading profits) and nonreportable traders (usually small traders/speculators). Find CFTC criteria here: (http://www.cftc.gov/MarketReports/CommitmentsofTraders/ExplanatoryNotes/index.htm).

Article By CountingPips.comReceive our weekly COT Reports by Email

Coverage Initiated on ‘Emerging Antibiotics Growth Story with Multiple Levers for Upside’

By The Life Science Report

Source: Streetwise Reports   09/19/2018

An H.C. Wainwright & Co. report outlined the investment thesis for this U.S.-based biopharmaceutical firm.

In a Sept. 11 research note, analyst Ed Arce reported that H.C. Wainwright & Co. launched coverage on Melinta Therapeutics Inc. (MLNT:NASDAQ) with a Buy rating and a $14 per share price target. The stock of this antibiotics developer is currently trading at around $4.62 per share.

The company is primarily focused on its four marketed drugs: Orbactiv, Minocin, Vabomere and Baxdela, the latter two having been approved and launched recently.

Management estimates the peak sales potential of this drug suite is $1 billion. “We believe this scenario is a plausible projection (if perhaps near the high end), especially if Baxdela is approved for community-acquired bacterial pneumonia,” Arce indicated. H.C. Wainwright, however, has based its target price on a more conservative peak sales forecast of $706 million, occurring in 2026.

Arce posited that product growth trends, a low valuation, several near-term catalysts and a healthy pipeline make Melinta attractive. “We view the 68.3% share price drop since March 8 as overdone and believe, at current levels, Melinta offers a compelling risk/reward, both in the near term and over the longer term,” he added.

The analyst suggested those interested in investing in Melinta buy sooner rather than later, “before the growth trends become obvious.” For example, growth drivers already in place include:

1) The addition this summer of 58 sales representatives, the full effects of which management anticipates in Q4/18.

2) The completion in August of cross-training the 170 sales representatives on all four products.

3) The Centers for Medicare & Medicaid Services having granted Vabomere a new technology add-on payment effective Oct. 1, providing up to 50% reimbursement ($5,544 at most) for Medicare patients plus the standard diagnosis-related group payment.

Another reason to buy now is Melinta’s “near rock bottom” valuation, wrote Arce. The company’s market cap and enterprise value are lower than what the company paid to acquire The Medicines Co.’s infectious disease business in January. “Several one-time items in Q2/18 related to the infectious disease business integration and optimization may be masking the true underlying growth and leverage of the business,” he added.

As for catalysts, Melinta has three expected in the near term, Arce noted:

1) Topline results by year-end 2018 for the Phase 3 community-acquired bacterial pneumonia study of intravenous-to-oral Baxdela versus the active comparator moxifloxacin/linezolid. If positive, the next steps are filing a supplemental new drug application in Q1/19, a six-month priority review subsequently and, finally, commercial launch in late 2019.

2) A European Medicines Agency decision on Vabomere, likely in Q4/18. “We believe approval is highly likely, with an announcement probably in November.” This approval “would enable and accelerate the third near-term milestone, which is to execute on ex-U.S. partnership(s) for Vabomere, Orbactiv and Minocin.”

3) Approval decisions from respective regulatory agencies, expected in Q1/18, for Melinta’s partners to market Baxdela in the European Union and in Argentina.

Melinta’s pipeline remains robust, with the company continuing to work on advancing its drug candidates. They include its lead pyrrolocytosine compound and its Phase 2 radezolid, a novel oxazolidinone class antibiotic for acne vulgaris and, on a qualified infectious disease product basis, for bacterial vaginosis.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Disclosures from H.C. Wainwright & Co., Melinta Therapeutics Inc., Initiating Coverage, Sept. 11, 2018

I, Ed Arce, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst’s household has a financial interest in the securities of Melinta Therapeutics, Inc., Achaogen, Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals, Inc., Spero Therapeutics, Inc. and Tetraphase Pharmaceuticals, Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of August 31, 2018 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Melinta Therapeutics, Inc., Achaogen, Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals, Inc., Spero Therapeutics, Inc. and Tetraphase Pharmaceuticals, Inc..

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The Firm or its affiliates did not receive compensation from Melinta Therapeutics, Inc., Achaogen, Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals, Inc. and Tetraphase Pharmaceuticals, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

The Firm or its affiliates did receive compensation from Spero Therapeutics, Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Spero Therapeutics, Inc. during the past 12 months.

The Firm does not make a market in Melinta Therapeutics, Inc., Achaogen, Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals, Inc., Spero Therapeutics, Inc. and Tetraphase Pharmaceuticals, Inc. as of the date of this research report.

( Companies Mentioned: MLNT:NASDAQ,
)

GB100 Analysis – Improving UK statistics bullish for GB100

By IFCMarkets

Improving UK statistics bullish for GB100

UK inflation and retail sales in August were better than forecast, indicating more robust economy than expected. Will the GB100 climb continue?

In the last couple of days UK economic data were better than expected. Retail sales rose 0.3% over month in August instead of an expected 0.2% decline. And inflation jumped to a six-month high of 2.7% from 2.5% when a decline to 2.4% was forecast. Earlier reports had indicated UK trade deficit narrowed drastically to £111 million in July from £942 million in June. And while the UK industrial output expansion slowed it still recorded 0.1% on month growth. At the same time wage growth accelerated in July. Stronger UK figures are bullish for GB100.

GB100 uptrend develops 09/21/2018 Technical Analysis IFC Markets chart

On the daily timeframe GB100: D1 is retracing higher after trading with negative bias for four months.

We believe the bullish momentum will continue after the price breaches above the upper Donchian boundary at 7387.97. This level can be used as an entry point for placing a pending order to buy. The stop loss can be placed below the lower Donchian channel at 7219.17. After placing the pending order the stop loss is to be moved every day to the next fractal low, following Parabolic signals. Thus, we are changing the probable profit/loss ratio to the breakeven point. If the price meets the stop-loss level (7219.17) without reaching the order (7387.97) we recommend cancelling the order: the market sustains internal changes which were not taken into account.

Technical Analysis Summary

Position Buy
Buy Stop Above 7387.97
Stop loss Below 7219.17

Market Analysis provided by IFCMarkets

Dow closes above January record

By IFCMarkets

Dollar weakening accelerated despite Dow, SP500 hitting records

US stock market rally continued on Thursday supported by more positive data and all but two Dow components. The S&P 500 added 0.8% to record high 2930.75. Dow Jones industrial average rallied 1% to first record after January at 26656. TheNasdaq composite climbed 1% to 8028.23. The dollar weakening continued at faster pace despite the report the Philadelphia Fed manufacturing index jumped more than expected in September, rising to 22.9 from 11.9 in August: the live dollar index data show the ICE US Dollar index, a measure of the dollar’s strength against a basket of six rival currencies, fell 0.7% to 93.865 and is lower currently. Futures on stock indices point to higher openings today.

DJI closes above January levels 09/21/2018 Market Overview IFCM Markets chart

DAX 30 opens higher than other European markets

European stocks extended gains on Thursday led by banking and mining shares. The EUR/USD rally accelerated andGBP/USD joined EUR/USD’s climb after surprise UK sales gain of 0.3% in August instead of an expected 0.2% decline. It is lower currently while the EUR/USD advance continues. The Stoxx Europe 600 index rose 0.5%. Germany’s DAX 30 advanced 0.9% to 12326.48. France’s CAC 40 rallied 1.1% and UK’s FTSE 100 added 0.5% to 7367.32. Indices opened 0.2% – 0.6% higher today

Chinese stocks lead Asian indices rally

Asian stock indices are rebounding today led by Chinese shares. Nikkei ended 0.8% higher at 23869.93 helped by accelerating yen decline against the dollar. Chinese stocks are recovering from multi-day losses after Beijing pledged to accelerate infrastructure spending and issues directives to boost consumption: the Shanghai Composite Index is 2.5% higher and Hong Kong’s Hang Seng Index is up 1.7%. Australia’s All Ordinaries Index rebounded 0.4% despite Australian dollar’s persisting climb against the greenback.

Brent gains on US inventories fall

Brent futures prices are gaining today after a pullback Thursday. Prices ended lower yesterday after President Trump tweeted for the Organization of the Petroleum Exporting Countries to “get prices down now!”: Brent for November settlement closed 0.9% lower at $79.83 a barrel on Thursday.

Market Analysis provided by IFCMarkets

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

Medical Use of Nitric Oxide Expands as Costs Come Down

By The Life Science Report

Source: Streetwise Reports   09/19/2018

Dr. Brett Earl, a practicing physician and a vice president and director of Nu-Med Plus, discusses the many uses of nitric oxide and Nu-Med Plus’ unique, low-cost delivery system.

The Life Sciences Report: Dr. Earl, thanks for joining us today. Would you tell us about yourself?

Brett Earl: I fell in love with medicine after following my home town family doctor around his practice and started to see the impact that he had in making a difference in people’s lives. Then I went through medical school and became board certified in emergency medicine. I practiced emergency medicine for 16 years.

Through a series of events, I became very sick myself. I ended up developing a fungal infection in my lungs. Fungal infections are very difficult to discover. They don’t show up on x-rays. They don’t show up on blood tests.

My illness drove me to study functional medicine and then, ultimately, foundational medicine, where instead of just looking at pills, prescriptions and surgery, we actually look at root source causes of disease and what’s triggering the underlying source of those diseases and the processes involved to restore health. What that means is that we can make dramatic changes in patients’ health at a foundational and underlying level. It’s very powerful as far as changing people’s lives.

I was able to get on the path of wellness and turn my health around. Getting excited about my own health improvements and then having the opportunity to spread that excitement to others is a very enjoyable process. When you know better, you do better. That was the case with myself. I knew of a better path and a better way. And I’ve since practiced functional and foundational medicine, and I look to help people regain their health rather than cover it up, mask it or cut it out.

TLSR: From there, what sparked your interest in nitric oxide?

BE: Since the discovery of the medical uses of nitric oxide by Dr. Louis Ignarro and others around 20 years ago, there have been over 60,000 research articles and research publications on the topic.

What we thought was just a simple molecule that offered vasodilation, or dilation of the blood vessels, we’re now finding has implications across the entire human body. It works as a neurotransmitter in the brain, so it actually helps the brain cells communicate between themselves. It has indications for our immune systems. It has dramatic assistance in the pulmonary system. And the list goes on and on and on.

What got me interested was the fact that it worked at such a foundational and fundamental level. Every cell in the body had some type of reaction or makes changes based on nitric oxide.

We talked about 60,000 articles that have been generated in the past 20 years. Additionally, researchers know of at least 675 different places throughout the human body where nitric oxide is used and benefits the body. So again, there isn’t anything more foundational and pure than that kind of interaction throughout the entire body.

TLSR: That’s interesting because you hear only about its use with premature babies and helping their lungs develop. So why is it that its wider uses aren’t well known?

BE: The uses are incredible and powerful, It is virucidal, meaning it kills most of the viruses. It kills most bacteria. It’s been shown to be effective in Ebola, malaria and many other seemingly incurable diseases. It is effective for trauma, post-stroke. It helps in pulmonary and respiratory disease. Nitric oxide has been extensively used in heart and vascular disease. The list is massive. It’s very effective and helps with almost all diseases. That said, to your question, with so many incredible uses, why isn’t it more widely available and used?

Well, it comes down to one very important thing: cost. Up until now, and I’m using a generalization of numbers, a relatively small canister of nitric oxide can cost upwards of $9,000–15,000. By the time the nitric oxide is actually applied to the patient through trained personnel who have the expertise with the devices that are necessary for delivery, it becomes very, very expensive. My understanding is that in the case of many newborn premature patients, the expense can run $75,000 by the time they finish their care. And that’s a very difficult expense to swallow. That is why it is currently reserved for only the most precious of patients.

A nutrient or a chemical that is very expensive becomes frowned upon when used for simple things, such as wound healing, which nitric oxide works for; instrument and workplace sterilization, which it works for; improving the way that a heart patient is treated in the catheter lab, etc. In each of those scenarios, cost becomes a very real consideration. Cost becomes the limiting factor. In today’s medical market, nitric oxide is not even given a chance to succeed in a patient treatment scenario.

Research is being done because there are often funds for research, and labs can often get the product for a lesser cost. But from a patient standpoint, it’s been very cost prohibitive.

TLSR: Is the gas always inhaled as a treatment? Or are there situations where it’s placed on the skin?

BE: The research has looked at both of those scenarios: treating an open wound versus treating internal processes. If it’s internal, then it would be something that would be inhaled. And when treating an open wound, then research has shown that it speeds healing and increases blood flow to the area that needs increased nutrients and oxygen delivery. And, again, nitric oxide sterilizes the area from other bacteria.

TLSR: You talked about the cost consideration. Can you talk about what’s now been happening with the patents for nitric oxide and what might be changing at this point?

BE: Most of the patents were based on a certain process for making nitric oxide. Because of the limited number of processes and the patent associated with them, there was really one option as far as purchasing nitric oxide.

Over the last few years, research has looked at different ways to produce nitric oxide. There is the Spark process, which is where they pass the chemicals into a chamber and then pass electrical current through. That process gains a certain amount of the nitric oxide. The largest challenges with this technology is the heat and energy necessary to generate the nitric oxide, and the purity of the product.

Nu-Med Plus Inc. (NUMD:OTC.MKTS) uses a completely different method from any of the previous processes. That’s why it’s been able to be patented and has implications for uses from the hospital setting to Third-World countries. The technology is both sophisticated, elegant and portable. The Nu-Med process can also make canisters that are very pure that can be used with the current medical systems. It produces a nitric oxide product that uses very low to no heat, and is much, much safer. It’s not going to be a risk as far as combustion in the healthcare setting, where there are likely other flammable chemicals and therapies around the patient. And finally, it just is much more cost effective as far as getting it into the hands that need it.

TLSR: What is the situation with getting the right approvals from the U.S. Food and Drug Administration (FDA) for Nu-Med’s product at this point?

BE: I do know that it has received multiple patents, and Nu-Med is finalizing FDA approval. A 501(k) is in the works.

TLSR: Do you have any sense of how much cost savings this would be over the existing suppliers of nitric oxide?

BE: There are some initial setup costs and some costs with equipment. But otherwise, the cost savings is significant. It is to the point that when this gets approved, it will have helpful indications throughout the medical universe from neurosurgery to Third-World countries. Nitric oxide delivered in this manner will be helpful for an innumerable host of research and medical applications.

There is a three-day conference in Europe—with the latest one being held in Oxford, England—where teams of researchers do nothing but talk about their research and indications for nitric oxide. This conference lasts for three days.

Just from an emergency medicine standpoint alone, there are indications for patients with heart attacks, high blood pressure, pulmonary issues, be that chronic obstructive pulmonary disease, difficulty breathing, asthma and so forth. Stroke patients will benefit from it. Trauma patients and wound care patients will see positive effects. Patients who have some type of vascular issue in their legs can be helped. Infections, post-surgical patients. . .the list just goes on and on and on. Furthermore, outside of the United States there are infections that absolutely devastate mankind that will be benefitted.

TLSR: What else should we know?

BE: One of the other indications and issues that we’ve alluded to is the research component. Yes, there’s a lot of research going on, but more research is only hampered by the availability of nitric oxide. This is one of the areas that Nu-Med has also focused on. We have a hospital unit. We have portable units. We have a clinic unit. And then we also have a research unit. That research unit allows nitric oxide to be used and delivered right where it is needed, again at considerable convenience and savings. One can only imagine that if suddenly more research could be done for less money then that the research will expand exponentially.

TLSR: Thanks for your time, Dr. Earl.

Dr. Brett Earl serves as the vice president of medical marketing for Nu-Med Plus and sits on its board of directors. He is a Board-Certified Emergency Physician with more than 15 years of experience in Emergency Medicine and more than a decade in Functional Medicine Physician. He is currently the president and founder of Denali Medical Center. Dr. Earl received his medical degree from the University of Nevada, Reno. He has been published in numerous medical journals and serves on various medical boards in Utah.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Patrice Fusillo conducted this interview for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She owns, or members of her immediate household or family own, shares of the following companies mentioned in this article: None. She is, or members of her immediate household or family are, paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this interview are billboard sponsors of Streetwise Reports: Nu-Med Plus. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

3) Dr. Brett Earl: I, or members of my immediate household or family, own shares of the following companies mentioned in this article: Nu-Med Plus. I, or members of my immediate household or family, are paid by the following companies mentioned in this article: Nu-Med Plus. My company has a financial relationship with the following companies mentioned in this interview: None. I determined which companies would be included in this article based on my experience using nitric oxide and no formal understanding of the sector. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview. I have not confirmed the exact costs of nitric oxide mentioned in this interview.
4) The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

( Companies Mentioned: NUMD:OTC.MKTS,
)

Cancer Vaccine Developer Expands Its Collaboration with Merck

By The Life Science Report

Source: Streetwise Reports   09/19/2018

A Mackie Research Capital report tells how this biotech will benefit from its new and existing programs with this specific partner.

In a Sept. 11 research note, Mackie Research Capital analyst Andre Uddin reported that IMV Inc. (IMV:TSX; IMMVD:OTCQX) is again collaborating with Merck, this time evaluating its DPX-Survivac with Merck’s Keytruda and low dose cyclophosphamide in a Phase 2 trial involving patients with certain advanced or recurrent solid tumors. This particular study will be of the basket variety, meaning it will evaluate treatment effects in multiple tumor types with a common molecular target, regardless of the tumor’s site of origin.

The two companies will share the cost, the details of which have not been released.

As far as potential benefits to IMV of the collaborative study, it “would further expand DPX-Survivac’s potential indications to additional tumor types, which should elevate the candidate’s licensing value and, ultimately, market potential,” Uddin indicated.

Specifically, this open-label, multicenter, Phase 2 basket trial will evaluate the safety and efficacy of the therapeutic regimen in 200 patients who have bladder, liver, ovarian or nonsmall cell lung cancer as well as in tumors with the microsatellite instability high biomarker. Uddin explained that “microsatellite instability is a condition of genetic hypermutability that plays a role in tumor progression.”

This study is slated to start in Q4/18. “The trial has an adaptive design, which implies if there is a sign of strong clinical activity in a relatively small number of patients, IMV and Merck can continue and accelerate the trial including targeting accelerated approval for each indication,” the analyst added.

Uddin pointed out that including this recently announced agreement, IMV now has three clinical programs with Merck, all investigating the use of DPX-Survival in combination with Keytruda. “Positive outcomes of the studies with DPX-Survivac should facilitate a potential licensing deal,” he purported.

The results of the two already underway are expected in the near term. Preliminary data from the trial of diffuse large B-cell lymphoma are anticipated in Q3/18 and those from the study in ovarian cancer are expected in H2/18. Topline results from both trials are anticipated in late 2018/early 2019.

Mackie maintains its Speculative Buy rating and CA$10.40 per share target price on IMV. The company’s stock is currently trading at about CA$6.83 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Disclosures from Mackie Research Capital Corp., IMV Inc., Update, Sept. 11, 2018

RELEVANT DISCLOSURES APPLICABLE TO COMPANIES UNDER COVERAGE:
Relevant disclosures required under IIROC Rule 3400 applicable to companies under coverage discussed in this research report are available on our web site at www.mackieresearch.com.
1. On January 9, 2015, Andre Uddin visited Immunovaccine’s headquarters and operations in Halifax, and viewed the laboratories, administrative offices, research centres, animal facilities, and small scale manufacturing area. MRCC paid all expenses.
2. MRCC is a market maker of Immunovaccine Inc.

ANALYST CERTIFICATION
Each analyst of Mackie Research Capital Corporation whose name appears in this report hereby certifies that (i) the recommendations and opinions expressed in this research report accurately reflect the analyst’s personal views and (ii) no part of the research analyst’s compensation was or will be directly or indirectly related to the specific conclusions or recommendations expressed in this research report.

( Companies Mentioned: IMV:TSX; IMMVD:OTCQX,
)

US stocks edge higher on positive data

By IFCMarkets

Dollar falls despite narrowing of current account deficit

US stock market extended gains on Wednesday as more positive data supported market sentiment while technology shares pulled back. The S&P 500 added 0.1% to 2907.95 led by financial shares up 1.8%. The Dow Jones industrial average rose 0.6% to 26405.76. Nasdaq composite index however lost 0.1% to 7950.04. The dollar strengthening reversed despite the Bureau of Economic Analysis report US current account deficit fell 17% in the second quarter and hit the lowest level in three years: the live dollar index data show the ICE US Dollar index, a measure of the dollar’s strength against a basket of six rival currencies, lost 0.5% to 94.527 and is falling currently. Futures on stock indices point to higher openings today.

DJI recovers to January levels 09/20/2018 Market Overview IFCM Markets chart

European stock markets open flat

European stocks added to previous session gains on Wednesday. The GBP/USD ended lower after initial boost following report UK inflation jumped to a six-month high of 2.7%. The EUR/USD’s climb continued and both pairs are higher currently. The Stoxx Europe 600 rose 0.3%. Germany’s DAX 30 gained 0.5% to 1219.02. France’s CAC 40 climbed 0.6% and UK’s FTSE 100 ended higher 0.4% at 7330.11. Indices opened flat today

Asian indices mixed

Asian stock indices are mixed today in cautious trade as trade war concerns linger after President Trump restated the US had “no choice” but to levy another $267 billion in duties on China. Nikkei ended 0.01% higher at 23674.93 as yen turned higher against the dollar. China’s stocks are mixed while Chinese Premier Li Keqiang said on Wednesday that the government will continue to lower import tariffs on some goods: the Shanghai Composite Index is down 0.1% and Hong Kong’s Hang Seng Index is 0.3% higher. Australia’s All Ordinaries Index however fell 0.3% with the Australian dollar steady against the greenback.

Brent gains on US inventories fall

Brent futures prices are edging higher today after gains yesterday following the Energy Information Administration report of surprise decline in US crude stockpile. Domestic crude supplies fell by 2.1 million barrels while the American Petroleum Institute on Tuesday reported an increase of 1.25 million barrels. Prices ended higher yesterday: November Brent crude rose 0.5% to $79.40 a barrel on Wednesday.

Market Analysis provided by IFCMarkets

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

U.S. Biotech Partner Obtains Marketing Authorization for ADHD Treatment in Taiwan

By The Life Science Report

Source: Streetwise Reports   09/18/2018

Permission has been obtained to distribute time-release capsules.

DURECT Corp. announced that Orient Pharma Co., Ltd., its licensee for certain Asian and South Pacific countries, has informed DURECT that it has obtained marketing authorization from the Ministry of Health and Welfare in Taiwan for Methydur Sustained Release Capsules.

“Methydur Sustained Release Capsules are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and will be available in three strengths (22 mg, 33 mg and 44 mg) in Taiwan,” stated the company. “Orient Pharma also has stated that it expects to have Methydur Sustained Release Capsules commercially available in Taiwan in 2019, while seeking a partner in China and pursuing regulatory approvals in selected other countries where it has commercialization rights and a commercialization presence.”

“We congratulate Orient Pharma on this new drug approval which will offer an alternative treatment for those patients suffering from ADHD in Taiwan,” said James E. Brown, president and CEO of DURECT Corporation. “We are pleased to see this first marketing approval for a product utilizing the ORADUR technology and the second recent approval of a product utilizing our patents.”

According to Orient Pharma, a phase 3, multi-center, randomized, double-blind, placebo controlled, two-way cross-over study designed to demonstrate the efficacy and safety of Methydur Sustained Release Capsules in children and adolescents with ADHD aged 6 to 18 years supported the new application.

“There were 110 subjects enrolled in this study, of which 100 evaluable subjects completed the study,” stated the company. “For the primary efficacy endpoint, Orient Pharma observed a statistically significant difference between Methydur Sustained Release Capsules and Placebo treatments in the mean change of total score for the Swanson, Nolan, and Pelham-IV (SNAP-IV) teacher form.”

Orient Pharma’s conducted a safety analysis that indicates that the incidence of adverse events with Methydur Sustained Release Capsules was similar to other approved Methylphenidate products.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) John McPhaul compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an employee. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: DURECT Corp. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

( Companies Mentioned: DRRX:NASDAQ,
)